JP2022550040A5 - - Google Patents
Info
- Publication number
- JP2022550040A5 JP2022550040A5 JP2022518837A JP2022518837A JP2022550040A5 JP 2022550040 A5 JP2022550040 A5 JP 2022550040A5 JP 2022518837 A JP2022518837 A JP 2022518837A JP 2022518837 A JP2022518837 A JP 2022518837A JP 2022550040 A5 JP2022550040 A5 JP 2022550040A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- atrop
- composition
- formula
- atropisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1913921.1 | 2019-09-26 | ||
| GB201913921A GB201913921D0 (en) | 2019-09-26 | 2019-09-26 | Pharmaceutical compounds |
| PCT/EP2020/076933 WO2021058754A1 (en) | 2019-09-26 | 2020-09-25 | Pharmaceutical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550040A JP2022550040A (ja) | 2022-11-30 |
| JP2022550040A5 true JP2022550040A5 (https=) | 2023-09-05 |
| JP7629452B2 JP7629452B2 (ja) | 2025-02-13 |
Family
ID=68539064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518837A Active JP7629452B2 (ja) | 2019-09-26 | 2020-09-25 | 医薬化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220348565A1 (https=) |
| EP (1) | EP4034246A1 (https=) |
| JP (1) | JP7629452B2 (https=) |
| KR (1) | KR102947064B1 (https=) |
| CN (1) | CN114585605B (https=) |
| AU (1) | AU2020356348B2 (https=) |
| BR (1) | BR112022005558A2 (https=) |
| CA (1) | CA3152320A1 (https=) |
| GB (1) | GB201913921D0 (https=) |
| IL (1) | IL291570B2 (https=) |
| MX (1) | MX2022003656A (https=) |
| WO (1) | WO2021058754A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202015187D0 (en) * | 2020-09-25 | 2020-11-11 | Sentinel Oncology Ltd | A pharmaceutical salt |
| CN116253706B (zh) * | 2022-12-26 | 2023-11-14 | 山东大学 | 一种靶向Siglec-9促进免疫细胞抗肿瘤和抗病毒功能小分子抑制剂及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| TW201500358A (zh) * | 2010-12-16 | 2015-01-01 | 赫夫門羅氏藥廠股份有限公司 | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| DE102014106986B4 (de) * | 2014-02-14 | 2023-10-12 | Samsung Display Co., Ltd. | Organische Moleküle mit kleinen Triplett-Singulett-Energieabständen für eine effektive verzögerte Fluoreszenz zur Anwendung in opto-elektronischen Vorrichtungen |
| GB201706806D0 (en) * | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
-
2019
- 2019-09-26 GB GB201913921A patent/GB201913921D0/en not_active Ceased
-
2020
- 2020-09-24 IL IL291570A patent/IL291570B2/en unknown
- 2020-09-25 WO PCT/EP2020/076933 patent/WO2021058754A1/en not_active Ceased
- 2020-09-25 KR KR1020227013520A patent/KR102947064B1/ko active Active
- 2020-09-25 MX MX2022003656A patent/MX2022003656A/es unknown
- 2020-09-25 BR BR112022005558A patent/BR112022005558A2/pt unknown
- 2020-09-25 JP JP2022518837A patent/JP7629452B2/ja active Active
- 2020-09-25 CN CN202080067040.1A patent/CN114585605B/zh active Active
- 2020-09-25 CA CA3152320A patent/CA3152320A1/en active Pending
- 2020-09-25 US US17/754,200 patent/US20220348565A1/en active Pending
- 2020-09-25 EP EP20789001.3A patent/EP4034246A1/en active Pending
- 2020-09-25 AU AU2020356348A patent/AU2020356348B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (https=) | ||
| EP2694485B1 (en) | Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments | |
| CN103635189B (zh) | 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗 | |
| JP2020514311A5 (https=) | ||
| JP2022121594A5 (https=) | ||
| TW202529768A (zh) | 癌症治療的療法 | |
| JP2019517487A5 (https=) | ||
| JP2013531038A (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| KR20170031786A (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| JP2017502092A5 (https=) | ||
| JP2015536997A5 (https=) | ||
| JP2024520630A5 (https=) | ||
| JP2023530316A5 (https=) | ||
| JP2007505044A5 (https=) | ||
| CN103841976A (zh) | Akt和mek抑制剂化合物的组合及其使用方法 | |
| JP2022550040A5 (https=) | ||
| JP2021512955A (ja) | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 | |
| JP2024125139A5 (https=) | ||
| JP2014504648A5 (https=) | ||
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| JP2021522246A (ja) | 癌治療のための併用 | |
| IL291570B1 (en) | Pharmaceutical preparations | |
| CN117355512A (zh) | 杂环衍生物、药物组合物及其在治疗或改善癌症中的用途 | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| CN105050602A (zh) | 作为pi3激酶抑制剂的吡啶化合物 |